S
Sowmya Bharath
Researcher at AstraZeneca
Publications - 19
Citations - 1590
Sowmya Bharath is an academic researcher from AstraZeneca. The author has contributed to research in topics: Mycobacterium tuberculosis & Plasmodium falciparum. The author has an hindex of 14, co-authored 17 publications receiving 1370 citations.
Papers
More filters
Journal ArticleDOI
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Vadim Makarov,Giulia Manina,Katarína Mikušová,Ute Möllmann,O. B. Ryabova,Brigitte Saint-Joanis,Neeraj Dhar,Maria Rosalia Pasca,Silvia Buroni,Anna Paola Lucarelli,Anna Milano,Edda De Rossi,Martina Belanova,Adela Bobovská,Petronela Dianišková,Jana Korduláková,Claudia Sala,Elizabeth Fullam,Patricia Schneider,John D. McKinney,Priscille Brodin,Thierry Christophe,Simon J. Waddell,Philip D. Butcher,Jakob Albrethsen,Ida Rosenkrands,Roland Brosch,Vrinda Nandi,Sowmya Bharath,Sheshagiri Gaonkar,Radha Shandil,V. Balasubramanian,Tanjore S. Balganesh,Sandeep Tyagi,Jacques H. Grosset,Giovanna Riccardi,Stewart T. Cole +36 more
TL;DR: The synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB are described.
Journal ArticleDOI
Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy
Radha Shandil,Ramesh Jayaram,Parvinder Kaur,Sheshagiri Gaonkar,B. L. Suresh,B. N. Mahesh,R. Jayashree,Vrinda Nandi,Sowmya Bharath,V. Balasubramanian +9 more
TL;DR: A lack of intracellular killing predicted the lack of in vivo activity of CIP, and the in vivo rank order for maximal efficacy of the three active fluoroquinolones was not clearly predicted by the in vitro assays.
Journal ArticleDOI
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
Ramesh Jayaram,Radha Shandil,Sheshagiri Gaonkar,Parvinder Kaur,B. L. Suresh,B. N. Mahesh,R. Jayashree,Vrinda Nandi,Sowmya Bharath,E. Kantharaj,V. Balasubramanian +10 more
TL;DR: Dose fractionation studies demonstrated that the 24-h area under the concentration-time curve/MIC correlated best with the bactericidal efficacy, followed by the maximum concentration of drug in serum/MIC (r2 = 0.73).
Journal ArticleDOI
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
Pravin S. Shirude,Radha Shandil,Claire Sadler,Maruti Naik,Vinayak Hosagrahara,Shahul Hameed,Vikas Shinde,Chandramohan Bathula,Vaishali Humnabadkar,Naveen Kumar,Jitendar Reddy,Vijender Panduga,Sreevalli Sharma,Anisha Ambady,Naina Hegde,James D. Whiteaker,Robert E. McLaughlin,Humphrey Gardner,Prashanti Madhavapeddi,Vasanthi Ramachandran,Parvinder Kaur,Ashwini Narayan,Supreeth Guptha,Disha Awasthy,Chandan Narayan,Jyothi Mahadevaswamy,K. G. Vishwas,Vijaykamal Ahuja,Abhishek Srivastava,K.R. Prabhakar,Sowmya Bharath,Ramesh R. Kale,Manjunatha Ramaiah,Nilanjana Roy Choudhury,Vasan K. Sambandamurthy,Suresh Solapure,Pravin Iyer,Shridhar Narayanan,Monalisa Chatterji +38 more
TL;DR: 1,4-azaindoles is reported as a new inhibitor class that kills Mycobacterium tuberculosis in vitro and demonstrates efficacy in mouse tuberculosis models and has the potential to be developed as a therapy for drug-sensitive and drug-resistant tuberculosis.
Journal ArticleDOI
Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.
Subramanyam J. Tantry,Shankar D. Markad,Vikas Shinde,Jyothi Bhat,Gayathri Balakrishnan,Amit K. Gupta,Anisha Ambady,Anandkumar Raichurkar,Chaitanyakumar Kedari,Sreevalli Sharma,Naina Vinay Mudugal,Ashwini Narayan,C. N. Naveen Kumar,Robert Nanduri,Sowmya Bharath,Jitendar Reddy,Vijender Panduga,K.R. Prabhakar,Karthikeyan Kandaswamy,Ramanatha Saralaya,Parvinder Kaur,Neela Dinesh,Supreeth Guptha,Kirsty Rich,David Murray,Helen Plant,Marian Preston,Helen Ashton,Darren Plant,Jarrod Walsh,Peter J. Alcock,Kathryn Naylor,Matthew Collier,James D. Whiteaker,Robert E. McLaughlin,Meenakshi Mallya,Manoranjan Panda,Suresh Rudrapatna,Vasanthi Ramachandran,Radha Shandil,Vasan K. Sambandamurthy,Khisi Mdluli,Christopher B. Cooper,Harvey Rubin,Takahiro Yano,Pravin Iyer,Shridhar Narayanan,Stefan Kavanagh,Kakoli Mukherjee,V. Balasubramanian,Vinayak Hosagrahara,Suresh Solapure,Sudha Ravishankar,Shahul Hameed P +53 more
TL;DR: The discovery of two diverse lead series imidazo[1,2-a]pyridine ethers and squaramides as inhibitors of mycobacterial ATP synthesis is reported, establishing a robust structure-activity relationship of these two scaffolds, resulting in nanomolar potencies in an ATP synthesis inhibition assay.